N-羟基酪氨酸 | 64448-49-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-羟基酪氨酸
• 英文名称: N-Hydroxytyrosine
• 英文别名: (2S)-2-(hydroxyamino)-3-(4-hydroxyphenyl)propanoic acid
• CAS: 64448-49-3
• 化学式: C₉H₁₁NO₄
• 分子量: 197.19
• InChiKey: CNIUEVQJABPUIJ-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  89.8
• 氢给体数：
  4
• 氢受体数：
  5

安全信息

• 海关编码：
  2922509090

文献信息

• Chemoselective Rapid Azo-Coupling Reaction for Bioconjugation
  申请人：Trustees of Boston College

  公开号：US20180360984A1

  公开（公告）日：2018-12-20

  Novel biomolecular conjugates containing non-natural aromatic chemical moieties covalently coupled to a diazonium compound and methods of their use are disclosed.

  揭示了含有非天然芳香化学基团的新型生物分子共轭物，其与重氮化合物共价耦合，并公开了它们的使用方法。
• [EN] TYPE III DEIODINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA DÉSIODINASE DE TYPE III ET LEURS UTILISATIONS
  申请人：HADASIT MED RES SERVICE

  公开号：WO2015140792A1

  公开（公告）日：2015-09-24

  The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.

  本发明涉及抑制第三型去碘酶（DIO3）活性的化合物。本发明还涉及治疗或预防抑郁症、与其他精神疾病或一般医学疾病相关的抑郁症、适合使用已知抗抑郁药物治疗的疾病或状况，以及癌症的方法，特别是通过使用本发明的化合物。
• [EN] NOVEL DOSAGE FORM<br/>[FR] NOUVELLE FORME PHARMACEUTIQUE
  申请人：BIOTICA TECH LTD

  公开号：WO2013061052A1

  公开（公告）日：2013-05-02

  There is provided inter alia apharmaceutical dosage form fororal administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration.

  提供了一种口服药物剂型，包括桑格利非林作为活性成分，其中桑格利非林活性成分在口服后胃环境中受到酸性降解的保护。
• Polyphenolic Bioprecursors
  申请人：Delaire Sabine

  公开号：US20090215881A1

  公开（公告）日：2009-08-27

  Cosmetic and therapeutic, in particular dermatological bioprecursors have the formula [A] n —PP—[B] m wherein PP is a polyphenol radical in which each hydroxyl function is protected by a group A or a group B, A is a saturated or unsaturated, substituted or unsubstituted alkyl radical having 1 to 20 carbon atoms which is bonded to the polyphenol, n is an integer not less than 1, and B is a precursor of a biologically active molecule, which is also bonded to the polyphenol, and m is an integer also not less than 1.

  化妆品和治疗用途，特别是皮肤病学生物前体具有以下公式[A]n—PP—[B]m，其中PP是一个多酚基团，其中每个羟基功能都由基团A或基团B保护，A是一个饱和或不饱和的、取代或未取代的烷基基团，含有1至20个碳原子，与多酚结合，n是一个不小于1的整数，B是生物活性分子的前体，也与多酚结合，m也是一个不小于1的整数。
• [EN] PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS<br/>[FR] PEPTIDES POUR L'ACTIVATION DE LA SIGNALISATION CELLULAIRE DANS DES CELLULES OSTÉOPROGÉNITRICES
  申请人：UNIV CALIFORNIA

  公开号：WO2020018941A1

  公开（公告）日：2020-01-23

  The present invention provides compounds and pharmaceutical compositions of peptidomimetic ligands. The peptidomimetic ligands can be conjugated with phosphonate drugs. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal stem cells and for the surface of bone.

  本发明提供了肽类模拟配体的化合物和制药组合物。这些肽类模拟配体可以与膦酸盐药物结合。本发明的化合物和制药组合物由于其对于骨髓干细胞上的α4β1整合素和骨表面的特异性而可用于治疗骨质疏松症和促进骨生长。